Performance · Recovery · Longevity

Shopping Cart (0)

Catalogue

Shop

Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).

Research peptides & wellness compounds

Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.

Semaglutide 5mg Pre-filled Pen

Category:
Weight Loss / Metabolic / Longevity
Price:
R 1880.00
{{variant.name}}:
{{opt.name}}
{{opt.value ? '' : opt.name}}
{{opt.value ? '' : opt.name}}
Description

TEST RUN WELLNESS Maglira 5 | Semaglutide 5mg Multi-Dosage Pre-Filled Pen

 

Maglira 5 (Semaglutide 5mg) – High-grade GLP-1 receptor agonist for weight loss and glucose management. Convenient multi-dosage pen with 8 needles included. Fast SA delivery from Test Run Wellness.

 

Product Overview

Maglira 5 is a Semaglutide 5mg multi-dosage pre-filled pen. Semaglutide is a long-acting GLP-1 receptor agonist with 94% sequence homology to native human GLP-1, engineered for once-weekly subcutaneous administration. The 5mg pen provides a multi-dose format with 8 needles included, supporting a structured titration pathway from the starter dose through to maintenance therapy.

 

How Semaglutide Works: GLP-1 Receptor Agonist Pathway

Semaglutide selectively binds to and activates the GLP-1 receptor, the same target as endogenous glucagon-like peptide-1. Its prolonged half-life is achieved through albumin binding, which decreases renal clearance and protects the molecule from metabolic degradation, enabling once-weekly dosing.

 

The mechanism operates across three domains. Centrally, semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem to reduce food intake and enhance satiety. Preclinical work has identified AP/NTS Adcyap1+ neurons in the dorsal vagal complex as essential mediators of semaglutide-induced weight loss, with these neurons promoting the loss of fat rather than lean mass . Peripherally, semaglutide improves glycaemic control by stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, alongside a minor delay in gastric emptying during the early postprandial phase . At the pancreatic level, it augments glucose-dependent insulin release from beta cells and suppresses elevated glucagon secretion by inhibiting pancreatic alpha cells .

 

Body Recomposition Benefits

Semaglutide produces substantial reductions in body weight and fat mass, with lean mass loss that is modest in absolute terms but can represent a meaningful proportion of total weight lost. In the SEMALEAN study of 106 patients with obesity treated with semaglutide 2.4 mg, total fat mass decreased by 14% at 7 months and 18% at 12 months.

 

Lean mass initially declined by approximately 3 kg at 7 months but stabilised thereafter, while handgrip strength improved significantly (+4.5 kg at 12 months) and the prevalence of sarcopenic obesity fell from 49% to 33% . A systematic review and network meta-analysis found that GLP-1 receptor agonists reduced lean mass by approximately 25% relative to total weight loss, with semaglutide 2.4 mg among the most effective for fat loss but among the least effective for preserving lean mass .

 

These findings underscore that semaglutide is a potent fat-loss agent, but body recomposition outcomes are optimised when therapy is paired with resistance exercise and adequate protein intake. The LEAN-PREP trial is directly testing whether resistance exercise and protein intake at 1.6 g/kg/day can preserve lean mass and physical function during semaglutide or tirzepatide therapy . Clinical strategies combining semaglutide with structured resistance training and high-protein nutrition are therefore recommended to shift the composition of weight lost toward fat while protecting skeletal muscle.

 

Titration Protocol

Semaglutide is administered as a once-weekly subcutaneous injection. The dose is escalated gradually over a minimum of 16 weeks to reach the maintenance dose of 2.4 mg once weekly, in order to reduce the likelihood of gastrointestinal symptoms.

 

Each dose is held for 4 weeks before increasing .

A standard escalation schedule is as follows:

· Weeks 1–4: 0.25 mg once weekly — starting dose for tolerance, not weight loss

 

· Weeks 5–8: 0.5 mg once weekly — first escalation

 

· Weeks 9–12: 1.0 mg once weekly — second escalation

 

· Weeks 13–16: 1.7 mg once weekly — third escalation

 

· Week 17+: 2.4 mg once weekly — maintenance dose

Dose escalation should only proceed if the current dose is well tolerated. Appetite changes typically become clear from 1 mg onward, and some individuals maintain adequate appetite control at 1 mg or 1.7 mg without reaching the maximum dose . If gastrointestinal symptoms are pronounced, escalation may be delayed or the dose reduced to the previous level.

 

Combination Therapy

Combination approaches with semaglutide are most advanced in the incretin and amylin space. The leading clinical combination is CagriSema, a fixed-dose combination of the long-acting amylin analogue cagrilintide (2.4 mg) and semaglutide (2.4 mg).

 

In the Phase 3 REDEFINE 1 trial, cagrilintide–semaglutide achieved an estimated mean weight change of –20.4% at week 68 versus –3.0% with placebo, with semaglutide alone at 2.4 mg achieving –14.9% and cagrilintide alone –11.5% . The complementary mechanisms — GLP-1 receptor agonism driving insulin secretion and satiety, with amylin receptor agonism enhancing insulin sensitivity and slowing gastric emptying — underlie the superior efficacy of the combination over either monotherapy .

Beyond CagriSema, semaglutide has been studied in combination with bimagrumab, an antibody blocking activin signalling, with research indicating greater weight loss alongside preservation of lean mass such as skeletal muscle and connective tissue . Co-administration with SGLT-2 inhibitors is also explored for glycaemic and cardiometabolic synergy. All combination approaches should be pursued under professional medical supervision.

 

Clinical Trial Record

Semaglutide has demonstrated robust efficacy across the STEP and SELECT clinical development programmes:

 

· STEP 1: Mean weight change of –14.9% at week 68 with semaglutide 2.4 mg versus –2.4% with placebo, corresponding to –15.3 kg versus –2.6 kg . In the DXA substudy, participants lost 10.4 kg (~25%) of fat mass alongside 6.9 kg (~13%) of lean soft tissue, with lean tissue accounting for approximately 40% of total weight lost .

 

· STEP 2 (T2D): Mean weight loss of 9.6%.

 

· SELECT: Once-weekly subcutaneous semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo in patients with atherosclerotic cardiovascular disease and obesity but without diabetes . The benefit was consistent in patients at risk for substantial liver fibrosis .

 

· REDEFINE 1 (CagriSema): Cagrilintide–semaglutide achieved –20.4% weight loss at week 68 versus –3.0% with placebo, with 14.9% for semaglutide alone .

Semaglutide is approved by regulatory authorities including the FDA, EMA, and MHRA for weight management and/or type 2 diabetes, depending on the specific product and indication. Maglira 5 is supplied by Test Run Wellness as a multi-dosage pre-filled pen with 8 needles included.

 

Technical Specifications

· Product Name: Maglira 5
· Peptide: Semaglutide
· Concentration: 5mg per pre-filled pen
· Form: Multi-dosage pre-filled pen
· Administration: Once-weekly subcutaneous injection
· What's In The Box: 1x 5mg Multi-Dosage Pen & 8x Needles
· Supplier: Test Run Wellness (Wellness.testrun)

 

Important Medical Notice

Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. Maglira 5 is intended for use under professional medical supervision. Semaglutide is a prescription medication in many jurisdictions and should only be used under appropriate medical oversight. Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during dose escalation. Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN2. All dosing information is derived from published clinical data and established titration protocols.

Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.